Linda Pan
Publications by Year
Research Areas
Immunotherapy and Immune Responses, vaccines and immunoinformatics approaches, Monoclonal and Polyclonal Antibodies Research, RNA Interference and Gene Delivery, Cancer Immunotherapy and Biomarkers
Most-Cited Works
- → Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming(2007)295 cited
- → Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients(2012)272 cited
- → Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer(2007)266 cited
- → Immunization of Malignant Melanoma Patients with Full-Length NY-ESO-1 Protein Using TLR7 Agonist Imiquimod as Vaccine Adjuvant(2008)244 cited
- → Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients(2006)214 cited
- → Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma(2012)145 cited
- → Regulatory T-Cell–Mediated Attenuation of T-Cell Responses to the NY-ESO-1 ISCOMATRIX Vaccine in Patients with Advanced Malignant Melanoma(2009)118 cited
- → Resiquimod as an Immunologic Adjuvant for NY-ESO-1 Protein Vaccination in Patients with High-Risk Melanoma(2015)91 cited
- → A phase I study of vaccination with NY‐ESO‐1f peptide mixed with Picibanil OK‐432 and Montanide ISA‐51 in patients with cancers expressing the NY‐ESO‐1 antigen(2011)81 cited
- → Effect of Montanide and Poly-ICLC Adjuvant on Human Self/Tumor Antigen-Specific CD4+ T Cells in Phase I Overlapping Long Peptide Vaccine Trial(2013)74 cited